Aktis Oncology Market Sentiment

Aktis Oncology Inc

AKTSNASDAQ

$18.15

0.412.31%

Last update: Oct 9, 3:59 PM

Aktis Oncology Market Sentiment - Benzinga

Market sentiment signals for Aktis Oncology (AKTS): analyst consensus, short interest, options flow and insider activity.

Analyst Consensus— Outperform

Short Interest▼ 20.1% short float

Options Flow— N/A

Insider Activity— Neutral (30d)

Analyst Consensus

Outperform

9 analysts

Options Flow (P/C)

—

Avg Consensus PT

$32

+73.4%

Highest Price Target

$40

+120.1%

Raymond James

Lowest Price Target

-94.5%

Piper Sandler

Short Interest

20.1%

Rising — Bearish

Insider Activity (30d)

Neutral

Short Interest — % of Float

Date	Firm	Analyst & Accuracy	Upside / Downside	PT Change	Action	Rating
Oct 2, 2026	Wedbush	David Nierengarten—	+92.6%	$35 → $35	Maintained	Outperform
Sep 9, 2026	Oppenheimer	Jeff Jones—	+120.1%	$40	Initiate	Outperform
Aug 19, 2026	Wedbush	David Nierengarten—	+92.6%	$35	Initiate	Outperform
Aug 19, 2026	BMO Capital	David Lebowitz—	+103.6%	$37	Initiate	Outperform
Jul 14, 2026	JP Morgan	Jessica Fye—	+81.6%	$30 → $33	Maintained	Overweight
Jun 16, 2026	Raymond James	Christopher Raymond—	+120.1%	$40	Initiate	Strong Buy
Jun 2, 2026	HC Wainwright & Co.	Robert Burns—	+92.6%	$33 → $35	Maintained	Buy
Apr 29, 2026	William Blair	Alexandra Ramsey—	—	—	Initiate	Outperform
Mar 31, 2026	HC Wainwright & Co.	Robert Burns—	+81.6%	$30 → $33	Maintained	Buy
Mar 9, 2026	HC Wainwright & Co.	Robert Burns—	+65.1%	$30	Initiate	Buy
Feb 3, 2026	Leerink Partners	——	+70.6%	$31	Initiate	Outperform
Feb 3, 2026	JP Morgan	Jessica Fye—	+65.1%	$30	Initiate	Overweight
Jan 4, 2024	Piper Sandler	Harsh Kumar—	-94.5%	$2 → $1	Downgrade	Overweight→Neutral